Furthermore, administration of miR-324-5p agonist could successfully rescue cytoskeleton remodeling and inflammatory response resulted from Dicer dyregulation, suggesting that miR-324-5p is a potential target for prevention and treatment of CRC. The gene discussed is DICER1; the disease is colorectal carcinoma.